OBJECTIVES: The Authors report the safety results of the extension phase of three multicenter, phase III studies, which evaluated ziprasidone in schizophrenic patients switching from another antipsychotic agent or who required a transition from intramuscular to oral ziprasidone.
PATIENTS AND METHODS: A total of 331 patients were evaluated, with a mean follow-up of 22 months (range: 3-73 months).
RESULTS AND CONCLUSIONS: Ziprasidone appeared well tolerated; most adverse events were of mild or moderate severity. No new safety or tolerability issues emerged. However, the authors observed a high number of withdrawals, possibly associated with a lack of long-term compliance, which is a common feature in schizophrenic patients.Free PDF Download
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
A. Sciarretta, G. Piazzi
Long-term safety of ziprasidone in schizophrenic patients: an open trial
Eur Rev Med Pharmacol Sci
Vol. 16 - N. 15